Chinanews.com, Shenzhen, August 17 (Zhu Zuying) The University of Hong Kong Shenzhen Hospital ("Hong Kong University Shenzhen Hospital") said on the 17th that the hospital introduced two new tumor drugs "Entratinib" through the "Hong Kong and Macao Medicines and Devices" policy. "Loratinib".

At present, two new tumor drugs have arrived and will soon be put into clinical use. They will provide alternative treatments for patients with refractory and specific gene mutation cancer types.

　　It is reported that this is the first batch of new oral anti-cancer drugs introduced since the “Hong Kong and Macao Medicines and Devices” policy was introduced in the Shenzhen Hospital of Hong Kong University. Batches of drugs put into clinical use.

Up to now, a total of 9 drugs and 2 devices have been put into clinical use in Hong Kong University Shenzhen Hospital one after another or will soon be put into use.

The picture shows the drug collection window of the Hong Kong Medicine Pass.

Photo courtesy of Hong Kong University Shenzhen Hospital

　　According to reports, both Entratinib and Loratinib are currently newer anti-cancer drugs approved globally.

Entratinib is the third pan-tumor anticancer drug in the world. It is used to treat adult and child patients with neurotrophic myosin receptor kinase (NTRK) fusion positive, locally advanced or metastatic solid tumor progression or no progression after initial treatment. Patients with solid tumors with standard treatment regimens and ROS1-positive non-small cell lung cancer (NSCLC) patients are not limited to tumor types, including pancreas, thyroid, salivary glands, breast, colorectal, and lung cancer.

　　Loratinib is currently the only third-generation anaplastic lymphoma kinase (Anaplastic Lymphoma Kinase) inhibitor approved for marketing. It is suitable for patients with ALK-positive advanced non-small cell lung cancer. With strong penetration ability, it is hoped that the survival period of such patients will be prolonged.

　　Li Yongmei, deputy dean of medical and teaching at the Hong Kong University Shenzhen Hospital and director of the Comprehensive Tumor Treatment Center, introduced that Entratinib is a representative drug for precision treatment of tumors, which allows tumor treatment to move from traditional "site therapy" to "gene therapy"; and The introduction of loratinib has brought new hope for treatment to some patients who have been sentenced to the death penalty in the past.

　　Prior to this, the first drug of the "Hong Kong and Macau Medicine Xiatong" "anti-D globulin injection" and the first device "magnetic controllable extension is great" were put into use at the Hong Kong University Shenzhen Hospital.

Ms. Yang, a pregnant woman who originally planned to go to Macau for injections, was injected with "anti-D immunoglobulin injection" at the Hong Kong University Shenzhen Hospital, becoming the first patient benefiting since the implementation of the "Hong Kong-Macau Medicines and Devices" policy; Director of the Orthopedic Medical Center of Hong Kong University Shenzhen Hospital and the world's first case" Zhang Wenzhi and his team successfully performed the operation on the 9-year-old child.

　　It is understood that as of August 15th, 165 “anti-D immunoglobulin injections” have been used (149 person-times), and the “magnetically controllable extension titanium rod” has also benefited 3 patients. There are currently no adverse reactions.

　　In addition, the "Hong Kong and Macao Medicines and Equipment Communication" policy has approved nine drugs and two medical devices that also include new drugs for the treatment of hematological tumors, severe chronic obstructive pulmonary disease, epilepsy and other diseases.

Some medicines have been delivered to the Hong Kong University Shenzhen Hospital and will be put into use in the near future.

(Finish)